Comparative Pharmacology
Head-to-head clinical analysis: RAUWOLFIA SERPENTINA versus SERPASIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUWOLFIA SERPENTINA versus SERPASIL.
RAUWOLFIA SERPENTINA vs SERPASIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.
None Documented
None Documented
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Terminal elimination half-life 45–168 hours (mean 100 h), reflecting prolonged adrenergic depletion; clinical effects persist beyond serum presence.
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Primarily renal (approx. 60% unchanged and metabolites), biliary/fecal (approx. 40%), enterohepatic circulation negligible.
Category C
Category C
Antihypertensive
Antihypertensive